BMY•benzinga•
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Summary
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a measure of innovation in drug research, tapered to merely one for the month.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 1, 2022 by benzinga